These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30214584)

  • 21. Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.
    Oh SY; Shin A; Kim SG; Hwang JA; Hong SH; Lee YS; Kwon HC
    Oncotarget; 2016 May; 7(21):31204-14. PubMed ID: 27144430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NRP-1 and KDR polymorphisms are associated with survival time in patients with advanced gastric cancer.
    Zhuo YJ; Shi Y; Wu T
    Oncol Lett; 2019 Nov; 18(5):4629-4638. PubMed ID: 31611971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.
    Dong N; Meng F; Wu Y; Wang M; Cui Y; Zhang S
    Tumour Biol; 2015 Sep; 36(10):7691-8. PubMed ID: 25934339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
    Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
    Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe loss of visceral fat and skeletal muscle after chemotherapy predicts poor prognosis in metastatic gastric cancer patients without gastrectomy.
    Feng W; Huang M; Zhao X; Chen S; Wang C; Chang J; Guo W; Chen Z; Zhu H; Zhu X
    J Cancer; 2020; 11(11):3310-3317. PubMed ID: 32231736
    [No Abstract]   [Full Text] [Related]  

  • 28. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma.
    Ma R; Liu C; Lu M; Yuan X; Cheng G; Kong F; Lu J; Strååt K; Björkholm M; Ma L; Xu D
    Urol Oncol; 2019 May; 37(5):301.e1-301.e10. PubMed ID: 30738744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
    Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
    Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
    Hubacek JA; Dlouha D; Adámkova V; Lanska V; Ceska R; Vrablik M
    Neuro Endocrinol Lett; 2012; 33 Suppl 2():22-5. PubMed ID: 23183505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
    Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
    Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
    Bins S; Lenting A; El Bouazzaoui S; van Doorn L; Oomen-de Hoop E; Eskens FA; van Schaik RH; Mathijssen RH
    Pharmacogenomics; 2016 Sep; 17(14):1483-90. PubMed ID: 27533851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
    Vasile E; Tibaldi C; Leon GL; D'Incecco A; Giovannetti E
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1189-94. PubMed ID: 25504507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
    Shitara K; Matsuo K; Ito S; Sawaki A; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Muro K
    Asian Pac J Cancer Prev; 2010; 11(2):447-52. PubMed ID: 20843132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
    Sawyer MB; Pituskin E; Damaraju S; Bies RR; Vos LJ; Prado CM; Kuzma M; Scarfe AG; Clemons M; Tonkin K; Au HJ; Koski S; Joy AA; Smylie M; King K; Carandang D; Damaraju VL; Hanson J; Cass CE; Mackey JR
    Clin Breast Cancer; 2016 Apr; 16(2):139-44.e1-3. PubMed ID: 26452313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
    Vulsteke C; Pfeil AM; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Peeters M; van Dam P; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
    Breast Cancer Res Treat; 2014 Oct; 147(3):557-70. PubMed ID: 25168315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
    Kim CO; Cho SK; Oh ES; Park MS; Chung JY
    J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.